NEW YORK – Veracyte said on Tuesday that it has partnered with Bayer to launch the Precision Oncology Patient Identification Program in thyroid cancer, which will focus on identifying patients who may benefit from biomarker-driven therapies.
NEW YORK – Veracyte said on Tuesday that it has partnered with Bayer to launch the Precision Oncology Patient Identification Program in thyroid cancer, which will focus on identifying patients who may benefit from biomarker-driven therapies.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.